English (UK)
中文版Dr. Amber Cai
Geneception is an innovation-driven biopharmaceutical company focusing on gene and cell therapy medicines.
Geneception Inc.
CEOMr. Yu Cai
Kawin Technology is a Chinese biopharma engaging in liver disease and virus-related disease.
The turnover in 2019 is over 800 million RMB (115 millon USD).
We are now in IPO process and projected to be listed in China this year.
The turnover in 2019 is over 800 million RMB (115 millon USD).
We are now in IPO process and projected to be listed in China this year.
Kawin
BD HEADAshley CAI
China largest PE fund which total size is over ten billion RMB.
China Structural Reform Fund
MDDr Cynthia Cai
Viva BioInnovator ("VBI") is the investment division of Viva Biotech Holdings (1873.HK). We are solely dedicated to the identification and success of early-stage, biotech start-ups for Viva’s incubation, equity-for-service, and investment platforms. Our commitment is to operate a collaborative platform for innovative biotech companies from around the world, and for anyone aiming to develop an idea with transformative or strong potential.
Viva Bioinnovator
Venture Partner
Emily Cao
Trespa is Top building material supplier and provide scientific surface solutions to laboratory environment. Our client includes Roche, BI, AZ, Pfizer, QiLu Pharma, Innocare , BASF etc
Trespa China Co., Ltd
Country ManagerMr. Jeff Cao
Our vision is: Curing cancer, pushing science to its limits and contributing to safe medical devices around the world!
As a medical device software specialist, we help MedTech startups get to their next milestone faster and safer. We have 20 years of experience and 220 in-house engineers to back you up and get you to the finish line - getting your device to market.
see less
As a medical device software specialist, we help MedTech startups get to their next milestone faster and safer. We have 20 years of experience and 220 in-house engineers to back you up and get you to the finish line - getting your device to market.
see less
ARROWFAST
VP CHINA
Eric Chang
Kaitai is a biotech venture fund with about 40 biotech portfolio companies. Kaitai's fund size is about 7 billions dollars. They are positively looking for cutting edge technologies.
Responsive Web Design powered by 